Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.

Inclusion Criteria:

• patients > 18 years and < 90 years,
• Patient diagnosed with DM
• Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm

Exclusion Criteria:

• patient who are not suitable for anticoagulant use,
• have thyroid dysfunction,
• glomerular filtration rate ≤ 25 ml/min/1.73 m²,
• patients whose sinus rhythm cannot be achieved with electrical cardioversion,
• malignancy patients,
• patients with acute or chronic inflammatory disease,
• patients with peripheral artery disease,
• patients with pacemakers,
• patients with advanced valve stenosis or insufficiency,
• patients who have had coronary bypass surgery,
• patients with percutaneous or surgical bioprosthesis or metallic valve surgery.

Patients diagnosed with DM and AF who were planned to undergo electrical cardioversion were evaluated for suitability for the study.